GlassScriptPhysician profile
Erwin C Puente
NPI 1003105677
$3,533.47
in general payments reported to CMS, 2019-2025
23 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 79% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $394 · 2021: $67.07 · 2022: $177 · 2023: $371 · 2024: $323 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,093.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $423.56 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $417.64 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $273.15 | 2023-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $254.67 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $208.86 | 2025 | Yutiq, Iluvien |
| Allergan, INC. | $189.34 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $185.68 | 2025 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $173.71 | 2025 | Eylea Hd |
| Harrow Eye, LLC | $167.68 | 2025 | Iheezo, Triesence |
| Genentech USA, INC. | $128.74 | 2024-2025 | Vabysmo |
| Genentech, INC. | $128.71 | 2025 | Susvimo |
| Kala Pharmaceuticals, INC. | $124.80 | 2019 | |
| Shire North American Group INC | $122.76 | 2019 | |
| Bausch & Lomb Americas INC. | $117.98 | 2025 | Xipere |
| Aerie Pharmaceuticals, INC. | $116.36 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $104.28 | 2025 | |
| Astellas Pharma US INC | $80.91 | 2023-2024 | Izervay |
| Eyepoint US, INC. | $71.73 | 2019-2023 | |
| Edwards Lifesciences Corporation | $71.04 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Coherus Oncology, INC. | $65.49 | 2023-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $65.09 | 2019 | |
| Sun Pharmaceutical Industries INC. | $25.14 | 2025 | |
| Alimera Sciences, INC. | $16.15 | 2024 | Yutiq, Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Puente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.